Reply to Chen <i>et al.</i>: Reexamining Chronic Obstructive Pulmonary Disease in Bronchiectasis: Elucidating Overdiagnosis and Outcomes from EMBARC’s ROSE Criteria-Reference-Cited by-同舟云学术

Reply to Chen et al.: Reexamining Chronic Obstructive Pulmonary Disease in Bronchiectasis: Elucidating Overdiagnosis and Outcomes from EMBARC’s ROSE Criteria

Published:2024-07-15 Issue:2 Volume:210 Page:248-249
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Chalmers James D.¹,De Soyza Anthony²,Aliberti Stefano³⁴,Polverino Eva⁵⁶

Affiliation:

1. Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, United Kingdom;

2. Population and Health Science Institute, Newcastle University and National Institute for Health and Care Research Biomedical Research Centre for Ageing, Freeman Hospital, Newcastle, United Kingdom;

3. Respiratory Unit, Scientific Institutes of Hospitalization and Care Humanitas Research Hospital, Milan, Italy;

4. Department of Biomedical Sciences, Humanitas University, Milan, Italy;

5. Pneumology Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Institut de Recerca, Vall d’Hebron Barcelona Hospital Campus, Biomedical Research Centre, Barcelona, Spain; and

6. Thorax Institute, Institute of Biomedical Research August Pi i Sunyer, University of Barcelona, Barcelona, Spain

Publisher

American Thoracic Society

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.202403-0476LE

Reference6 articles.

1. Clearing the Air: Innovations in Imaging for Early Detection and Management of Chronic Obstructive Pulmonary Disease

2. The Bronchiectasis Severity Index. An International Derivation and Validation Study

3. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC)

4. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials

5. Endotyping Chronic Obstructive Pulmonary Disease, Bronchiectasis, and the “Chronic Obstructive Pulmonary Disease–Bronchiectasis Association”